The analysis revealed that desmopressin might significantly decrease the frequency of nocturnal voids , nocturnal urine volume and nocturnal diuresis , potentially result ing in an extended duration of the first sleep period and improved sleep quality .
The adverse effects of desmopressin were similar to those observed in the placebo group .
Conclusions Administered desmopressin was an effective and well-tolerated treatment for nocturia
Purpose The purpose of this analysis was to evaluate the efficacy and safety of desmopressin for the treatment of nocturia .
Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study.
PURPOSE We evaluated the long-term efficacy and safety of low dose oral desmopressin in elderly patients with benign prostatic hyperplasia with more than nocturnal voids and nocturnal polyuria more than 30 % of total daily urine volume . MATERIAL S AND METHODS Eligible patients with benign prostatic hyperplasia older than 65 years with nocturia , nocturnal polyuria and International Prostate Symptom Score 14 or greater were included in the study . All patients received placebo or 0.1 mg desmopressin orally at bedtime . Patients were required to visit the outpatient clinic from the first visit , and after 1 , 3 , 6 and 12 months of treatment . Patients maintained flow volume charts and used diaries to record voiding data throughout the study . During followup urinalysis , urine sodium , urine osmolality , serum electrolytes , prostate specific antigen , International Prostate Symptom Score , quality of life , transrectal ultrasonography of prostate , uroflowmetry and post-void residual urine volume were performed at each visit . RESULTS A total of 115 patients were enrolled in the study and r and omized as 58 in the placebo group and 57 in the desmopressin group . Desmopressin significantly decreased nocturnal urine output and the number of nocturia episodes , and prolonged the first sleep period ( p < 0.01 ) . Compared to before treatment desmopressin gradually decreased serum sodium and induced statistically but not clinical ly significant hyponatremia after 12 months of treatment . No serious systemic complications were found during medication . CONCLUSIONS Low dose oral desmopressin is an effective and well tolerated treatment for nocturnal polyuria in the lower urinary tract symptoms of patients with benign prostatic hyperplasia . Long-term desmopressin therapy gradually decreases serum sodium and it might induce hyponatremia even in patients without initial hyponatremia . For long-term desmopressin administration serum sodium should be assessed carefully , at least at 1 week after treatment
The analysis revealed that desmopressin might significantly decrease the frequency of nocturnal voids , nocturnal urine volume and nocturnal diuresis , potentially result ing in an extended duration of the first sleep period and improved sleep quality .
The adverse effects of desmopressin were similar to those observed in the placebo group .
Conclusions Administered desmopressin was an effective and well-tolerated treatment for nocturia
Purpose The purpose of this analysis was to evaluate the efficacy and safety of desmopressin for the treatment of nocturia .